| 1. |
吉武忠正, 九州大学病院における寡分割照射の取り組みと治療システム, 第20回九州放射線治療システム研究会, 2022.02. |
| 2. |
吉武忠正, 浅井佳央里, 松本圭司, 白川友子, 稻盛真人, 中島孝彰, 樋渡昭雄, 佐々木智成, 西江昭弘, 秦暢宏, 塩山善之, 再発膠芽腫に対するベバシズマブ併用定位放射線治療の治療成績, 日本放射線腫瘍学会 第３２回学術大会, 2019.11. |
| 3. |
吉武忠正,野元 諭,大賀才路,浅井佳央里,松本圭司,平田秀成,中島孝彰,佐々木智成,本田浩, 肺定位放射線治療における近似症例を利用した治療計画支援システムの検証, 日本放射線腫瘍学会 第31回学術大会, 2018.10. |
| 4. |
吉武忠正、大賀才路、野元 諭、浅井佳央里、平田秀成、中島孝彰、上原隆治、髙木正統、佐々木智成、吉本幸司、本田 浩, Grade 2-3髄膜腫に対する高精度放射線治療成績, 日本放射線腫瘍学会第30回学術大会, 2017.11. |
| 5. |
Tadamasa Yoshitake, Satoshi Nomoto, Saiji Ohga, Toshihiro Yamaguchi, Kaori Asai, Hidenari Hirata, Osamu Hisano, Yushi Motomura, Daisuke Maruoka, Tomonari Sasaki, Hiroshi Honda, A preliminary result of computer-aided radiotherapy planning system using previous similar cases for stereotactic body radiotherapy, 第76回日本医学放射線学会総会, 2017.04. |
| 6. |
Tadamasa Yoshitake, Saiji Ohga, Satoshi Nomoto, Toshihiro Yamaguchi, Kaori Asai, Hidenari Hirata, Osamu Hisano, Yushi Motomura, Akio Hiwatashi, Koji Yoshimoto, Hiroshi Honda, High pre-treatment neutrophil-to-lymphocyte ratio predicts poor survival in patients with glioblastoma treated with radiotherapy and temozolomide, ASTRO2016, 2016.09. |
| 7. |
吉武 忠正, Incidence of radiation pneumonitis after multiple courses of stereotactic body radiation therapy for lung cancer patients, ASTRO, 2014.09. |
| 8. |
Tadamasa Yoshitake, Yoshiyuki Shioyama, Katsumasa Nakamura, Tomonari Sasaki, Ohga Saiji, Ｈｉｄｅｋｉ Ｈｉｒａｔａ, Hiroshi Honda, Stereotactic body radiation therapy for primary lung cancers which were clinically diagnosed without pathological confirmation: a single-institution experience, RSNA, 2012.11, Purpose
Pathological diagnosis of small lung lesions is sometimes difficult in inoperable patients. The purpose of the present study was to evaluate the outcome of stereotactic body radiotherapy (SBRT) for small lung lesions that are clinically diagnosed as primary lung cancer without pathologic confirmation.
Materials and methods
Between April 2003 and July 2011, 82 patients with small pulmonary lesions clinically diagnosed as primary lung cancer were treated with SBRT in Kyushu University Hospital. The median age of the 66 patients was 75 years (range 51- 92 years). Forty four patients were male, and 38 were female. The median tumor size was 19 mm (range 8-40 mm). Thin-section CT findings for these pulmonary lesions showed solid nodules and ground-glass opacity (GGO) nodules in 53 and 29 patients, respectively. The radiation dose was 48 Gy in 4 fractions in all patients.
Results
Median follow-up was 20 months (range 6-83 months). Recurrence was observed in 13 (15.9%) patients (local failure, 6; regional failure, 5; distant metastases, 6) with solid nodules. There was no recurrence in 29 patients with GGO nodules. Two patients died of recurrence and 10 patients died from other diseases. Local control rate, cause-specific survival and overall survival at 3 years were 88%, 98% and 79%, respectively. Two (2.4%) patients and 5 (6.1%) patients had grade 2 radiation pneumonitis and grade 2 rib fracturing, respectively. There were no adverse effects of grade 3 or greater during follow-up.
Conclusions
SBRT is to be considered a safe and effective treatment option for small lung lesions clinically diagnosed as primary lung cancer without pathologic confirmation, especially in patients with GGO nodules.
. |
| 9. |
吉武忠正, イブニングセミナー：放射線科医としての楽しみ, ミッドサマーセミナー2011, 2011.07. |
| 10. |
吉武 忠正, 塩山 善之, 大賀 才路, 野々下 豪, 大西 かよ子, 浅井 佳央里, 松本 圭司, 中村和正, 平田秀紀, 本田 浩
, 在宅酸素療法中の原発性肺癌患者に対する体幹部定位放射線治療, 日本放射線腫瘍学会学術大会第23回学術大会, 2010.11. |
| 11. |
Yoshitake T, Shioyama Y, Nakamura K, Ohga S, Nonoshita T, Ohnishi K, Asai K, Matsumoto K, Hirata H, Honda H., Dosimetric evaluation in stereotactic radiotherapy for pulmonary ground-glass opacity nodules: The relationship with calculation algorithm and dose prescription methods., Radiological Society of North America, 2010.12. |
